We next investigated if treatment with TAK-063 leads to increases in BDNF levels at 3 weeks following striatal stroke, a time point where heightened levels of BDNF post-stroke have been reported [6] and just before significant behavioral recovery with this drug is observed (Fig. 1a; Supplemental Fig. 3). The gene discussed is BDNF; the disease is stroke disorder.